These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33866938)

  • 1. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
    Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
    J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
    Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
    J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
    Zhu C; Han G; Wu B
    BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
    McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M
    J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
    Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M
    J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
    Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Amonkar M; Yao L; Jin F; Norwood K; Maio M
    Gynecol Oncol; 2022 Aug; 166(2):245-253. PubMed ID: 35835611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
    Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
    J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis.
    Zhu Y; Liu K; Zhu H
    Int J Gynecol Cancer; 2024 Oct; 34(10):1570-1579. PubMed ID: 38901970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
    Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
    BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Dilley SE; Smith HJ; Straughn JM
    Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Ackroyd SA; Huang ES; Kurnit KC; Lee NK
    Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
    Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
    J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
    Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
    Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
    J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer.
    Chongqing T; Sini L; Xiaohui Z; Liubao P; Ye P; Shuxia Q; Liting W; Meiyu W; Xiaomin W
    Front Pharmacol; 2021; 12():802942. PubMed ID: 34970153
    [No Abstract]   [Full Text] [Related]  

  • 20. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
    Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A
    Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.